Ars Pharmaceuticals, Inc. SPRY Stock Forecast
AI-powered price prediction and analysis for Ars Pharmaceuticals, Inc. · Alpha · vs marketSwitch to Total
See SPRY's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Ars Pharmaceuticals, Inc.
Ars Pharmaceuticals, Inc. (SPRY) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
- ARS Pharmaceuticals, Inc. (SPRY) reports Q4 loss, beats revenue estimates
- ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
- SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October …
- Sign up free to read all 9 articles →
Where SPRY sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| SPRY Ars Pharmaceuticals, Inc. | ▶ | $416M | – |
| LLY Eli Lilly & Co | ▲ | $1.10T | 41.1x |
| JNJ Johnson & Johnson | ▼ | $599.12B | 28.5x |
| ONC Beone Medicines Ltd. | ▶ | $517.93B | – |
| ABBV Abbvie Inc. | ▼ | $484.61B | 76.8x |
| MRK Merck & Co., Inc. | ▼ | $358.85B | 113.1x |
| NVS Novartis Ag | ▼ | $271.74B | – |
| GSK Gsk Plc | ▼ | $199.68B | – |
| ABT Abbott Laboratories | ▶ | $178.85B | 28.6x |
| PFE Pfizer Inc | ▲ | $161.87B | 37.4x |
| VRTX Vertex Pharmaceuticals Inc / … | ▼ | $128.50B | 29.2x |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B | 12.5x |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $78.54B | 18.1x |
| SNY Sanofi | ▼ | $48.46B | – |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.98B | 67.9x |
| RPRX Royalty Pharma Plc | ▲ | $33.22B | 40.8x |
| ZTS Zoetis Inc. | ▼ | $31.26B | 12.0x |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B | – |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.72B | – |
| ZLAB Zai Lab Ltd | ▼ | $27.60B | – |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.74B | – |
| ROIV Roivant Sciences Ltd. | ▶ | $24.99B | – |
| UTHR United Therapeutics Corp | ▼ | $23.59B | 18.0x |
| INSM Insmed Inc | ▶ | $21.14B | – |
| VTRS Viatris Inc | ▶ | $20.15B | – |
| ASND Ascendis Pharma A/S | ▶ | $13.83B | – |
| SMMT Summit Therapeutics Inc. | ▶ | $13.67B | – |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B | 14.5x |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B | – |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B | – |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B | – |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B | – |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B | – |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.70B | – |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B | – |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B | – |
| PTGX Protagonist Therapeutics, Inc | ▲ | $9.37B | – |
| CYTK Cytokinetics Inc | ▶ | $8.57B | – |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B | – |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B | – |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.57B | – |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B | – |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $7.02B | – |
| ABVX Abivax S.A. | ▼ | $6.83B | – |
| ALKS Alkermes Plc. | ▶ | $6.67B | – |
| LEGN Legend Biotech Corp | ▶ | $6.61B | – |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B | – |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $6.18B | – |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B | 30.7x |
| BLTE Belite Bio, Inc | ▲ | $5.97B | – |
| BLRX Biolinerx Ltd. | ▶ | $5.67B | – |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.59B | – |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.25B | – |
| ERAS Erasca, Inc. | ▲ | $5.17B | – |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.90B | – |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B | – |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B | – |
| MANE Veradermics, Inc | ▲ | $4.86B | – |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B | – |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B | – |
FAQ
Is Ars Pharmaceuticals, Inc. a good stock to buy?
Our AI analyzes Ars Pharmaceuticals, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Ars Pharmaceuticals, Inc. predictions?
A per-ticker accuracy statistic for SPRY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Ars Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Ars Pharmaceuticals, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.